NCT04216459View on ClinicalTrials.gov

Effect of Anti-inflammatory and Anti-microbial Co-supplementations in Traumatic ICU Patients at High Risk of Sepsis

NACompletedINTERVENTIONAL
Enrollment

112

Participants

Timeline

Start Date

February 18, 2020

Primary Completion Date

November 30, 2020

Study Completion Date

October 4, 2021

Conditions
Major TraumaSepsis
Interventions
DRUG

oral lactobacillus probiotics plus intramuscular cholecalciferol

According to leukocyte anti- sedimentation rate (LAR) result on day 1 patients will be classified into high risk for sepsis patients (LAR \< 15 %) and low risk for sepsis patients (LAR ≥ 15%) High risk sepsis patients will be randomly allocated into one of the 3 groups (sealed opaque envelops) to vitamin D plus probiotics intervention group (HR-DP) group. to vitamin C plus vitamin B intervention group (HR-CB) group. to control group (HR-C) group that does not receive any supplement

DRUG

intravenous vitamin C plus thiamine

starting from day 1 in a dose of 1 gm vitamin C and 200 mg thiamine intravenous 4 times at 12-hour intervals for 48 hours

Trial Locations (1)

Unknown

Mansoura University-Emergency hospital-ICU, Al Mansurah

All Listed Sponsors
lead

Mansoura University

OTHER

NCT04216459 - Effect of Anti-inflammatory and Anti-microbial Co-supplementations in Traumatic ICU Patients at High Risk of Sepsis | Biotech Hunter | Biotech Hunter